Profile data is unavailable for this security.
About the company
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.
- Revenue in USD (TTM)40.55m
- Net income in USD-43.84m
- Incorporated2013
- Employees32.00
- LocationSpero Therapeutics Inc675 Massachusetts Ave Ste 14CAMBRIDGE 02139-3309United StatesUSA
- Phone+1 (857) 242-1600
- Fax+1 (302) 655-5049
- Websitehttps://sperotherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Black Diamond Therapeutics Inc | 70.00m | 21.50m | 126.48m | 24.00 | 6.12 | 1.00 | 5.79 | 1.81 | 0.3629 | 0.3629 | 1.23 | 2.22 | 0.4736 | -- | -- | 2,916,667.00 | 14.54 | -42.24 | 16.58 | -46.05 | -- | -- | 30.71 | -- | -- | -- | 0.00 | -- | -- | -- | 15.48 | -- | -- | -- |
| AVITA Medical Inc | 72.40m | -48.56m | 127.43m | 260.00 | -- | -- | -- | 1.76 | -1.81 | -1.81 | 2.70 | -0.2186 | 1.00 | 1.63 | 7.50 | 278,461.50 | -67.07 | -- | -147.57 | -- | 84.81 | -- | -67.06 | -- | 0.5519 | -8.20 | 1.19 | -- | 28.14 | -- | -74.80 | -- | -- | -- |
| Oramed Pharmaceuticals, Inc. | 2.00m | 43.85m | 129.36m | 13.00 | 3.23 | 0.6529 | 2.94 | 64.68 | 1.01 | 1.01 | 0.0478 | 4.98 | 0.0104 | -- | -- | 153,846.20 | 22.72 | -- | 23.30 | -- | 0.65 | -- | 2,190.40 | -- | -- | -- | 0.00 | -- | -100.00 | -- | -444.98 | -- | -- | -- |
| Corbus Pharmaceuticals Holdings Inc | 0.00 | -67.51m | 132.70m | 28.00 | -- | 1.03 | -- | -- | -5.51 | -5.51 | 0.00 | 7.35 | 0.00 | -- | -- | 0.00 | -49.34 | -69.78 | -55.11 | -97.84 | -- | -- | -- | -5,894.85 | -- | -- | 0.00 | -- | -- | -- | 9.85 | -- | -- | -- |
| Unicycive Therapeutics Inc | 0.00 | -33.47m | 133.25m | 22.00 | -- | 3.45 | -- | -- | -2.85 | -2.85 | 0.00 | 1.80 | 0.00 | -- | -- | 0.00 | -74.93 | -188.44 | -101.88 | -723.53 | -- | -- | -- | -6,003.20 | -- | -- | 0.00 | -- | -100.00 | -- | -20.42 | -- | -- | -- |
| vTv Therapeutics Inc | 17.00k | -23.47m | 133.39m | 23.00 | -- | 1.89 | -- | 7,846.40 | -3.32 | -3.32 | 0.0024 | 17.91 | 0.0002 | -- | -- | 739.13 | -39.79 | -96.30 | -46.08 | -- | -- | -- | -166,935.30 | -775.06 | -- | -- | 0.0046 | -- | -- | -18.12 | 8.83 | -- | -- | -- |
| Spero Therapeutics Inc | 40.55m | -43.84m | 134.65m | 32.00 | -- | 5.08 | -- | 3.32 | -0.7949 | -0.7949 | 0.7299 | 0.4705 | 0.4283 | -- | 1.45 | 1,267,156.00 | -46.31 | -35.16 | -69.26 | -42.63 | -- | -- | -108.11 | -111.75 | -- | -- | 0.00 | -- | -53.77 | 21.46 | -400.65 | -- | -- | -- |
| Vaxart Inc | 148.20m | -50.70m | 135.88m | 105.00 | -- | 4.84 | -- | 0.9168 | -0.2222 | -0.2222 | 0.6495 | 0.1169 | 0.789 | -- | 3.31 | 1,411,467.00 | -26.99 | -49.90 | -80.48 | -58.33 | -- | -- | -34.21 | -875.06 | -- | -31.43 | 0.1161 | -- | 288.94 | 23.82 | 18.82 | -- | -8.21 | -- |
| Sangamo Therapeutics Inc | 32.88m | -108.91m | 138.20m | 183.00 | -- | 19.96 | -- | 4.20 | -0.4428 | -0.4428 | 0.1326 | 0.0194 | 0.3289 | -- | 5.97 | 179,644.80 | -108.96 | -30.73 | -204.29 | -37.33 | -- | -- | -331.28 | -147.59 | -- | -- | 0.00 | -- | -67.20 | -10.81 | 62.01 | -- | -58.10 | -- |
| HST Global Inc | 0.00 | -212.63k | 139.70m | 1.00 | -- | 8.48 | -- | -- | -0.0107 | -0.0107 | 0.00 | 0.1167 | 0.00 | -- | -- | -- | -6.87 | -27.80 | -8.09 | -60.19 | -- | -- | -- | -- | -- | -107.48 | 0.0433 | -- | -- | -- | -45.42 | -- | -- | -- |
| Nkarta Inc | 0.00 | -102.61m | 139.93m | 105.00 | -- | 0.4141 | -- | -- | -1.39 | -1.39 | 0.00 | 4.76 | 0.00 | -- | -- | 0.00 | -21.39 | -29.78 | -22.36 | -31.23 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.41 | -- | 17.99 | -- |
| Prelude Therapeutics Inc | 10.50m | -111.77m | 140.19m | 131.00 | -- | 2.16 | -- | 13.35 | -1.47 | -1.47 | 0.1382 | 1.03 | 0.0719 | -- | -- | 80,152.67 | -76.56 | -47.36 | -88.86 | -51.44 | -- | -- | -1,064.50 | -7,615.23 | -- | -- | 0.00 | -- | -- | -- | -4.38 | -- | -0.4137 | -- |
| Tenaya Therapeutics Inc | 0.00 | -94.26m | 141.07m | 97.00 | -- | 1.30 | -- | -- | -0.7875 | -0.7875 | 0.00 | 0.5061 | 0.00 | -- | -- | 0.00 | -76.77 | -47.44 | -87.21 | -51.82 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 10.44 | -- | -18.92 | -- |
| Fate Therapeutics Inc | 7.14m | -156.09m | 144.19m | 181.00 | -- | 0.616 | -- | 20.20 | -1.32 | -1.32 | 0.0603 | 2.03 | 0.017 | -- | 2.30 | 39,430.94 | -37.23 | -32.44 | -40.38 | -36.57 | -- | -- | -2,187.11 | -389.06 | -- | -- | 0.00 | -- | -78.55 | 5.00 | -15.74 | -- | -37.07 | -- |
| Milestone Pharmaceuticals Inc | 0.00 | -58.01m | 144.79m | 33.00 | -- | 7.06 | -- | -- | -0.8938 | -0.8938 | 0.00 | 0.2407 | 0.00 | -- | -- | 0.00 | -68.07 | -48.63 | -75.01 | -52.10 | -- | -- | -- | -1,201.96 | -- | -73.28 | 0.7327 | -- | -100.00 | -- | 30.44 | -- | -39.67 | -- |
| Connect Biopharma Holdings Ltd (ADR) | 762.00k | -50.77m | 145.35m | 62.00 | -- | 2.62 | -- | 190.75 | -0.9144 | -0.9144 | 0.0137 | 0.9926 | -- | -- | -- | 12,290.32 | -- | -61.12 | -- | -66.78 | -- | -- | -6,662.99 | -1,963.00 | -- | -- | 0.00 | -- | -- | -- | 74.84 | -- | 37.04 | -- |
Data as of Feb 13 2026. Currency figures normalised to Spero Therapeutics Inc's reporting currency: US Dollar USD
11.93%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 1.79m | 3.18% |
| Anson Funds Management LPas of 30 Sep 2025 | 1.60m | 2.85% |
| Renaissance Technologies LLCas of 31 Dec 2025 | 1.28m | 2.27% |
| Geode Capital Management LLCas of 31 Dec 2025 | 529.20k | 0.94% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 432.42k | 0.77% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 264.12k | 0.47% |
| The Informed Momentum Co. LLCas of 31 Dec 2025 | 218.08k | 0.39% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 210.15k | 0.37% |
| Ionic Capital Management LLCas of 30 Sep 2025 | 208.73k | 0.37% |
| GSA Capital Partners LLPas of 31 Dec 2025 | 178.93k | 0.32% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
